Research Bulletin — Internal Use Only Patafino Biomedical Laboratories Confidential Brief: Human Experimentation on Stage 4 Shikuo Virus Infectees Date: [REDACTED] Lead Researcher: Dr. V. Halstrom Location: Isolated Clinical Sector B-17, Patafino Compound Subject: Advanced Human Trials on Terminal-Stage Shikuo Virus Carriers Patafino has initiated controlled human experimentation on stage 4 infectees of the Shikuo virus, marking a controversial and ethically ambiguous phase in viral pathology research. At this stage of progression, the pathogen displays maximum neurological aggression, surpassing the blood-brain barrier and disrupting central nervous system integrity. Initial symptoms of stage 4 infection include: • Widespread dermal necrosis: Infected individuals develop extensive ulcerated sores and blackened lesions. Biopsies confirm accelerated cell death in dermal layers and sebaceous glands, accompanied by a rancid ammonia-like odor excreted from damaged tissue. • Loss of motor coordination: Neurological scans reveal degradation in the cerebellum and spinal cord. Subjects exhibit spasmodic convulsions followed by full paralysis in distal limbs. Fine motor functions cease within 12 hours of stage onset. • Auditory and visual hallucinations: 87% of monitored subjects reported spectral visions, disembodied voices, and heightened sensory distortion. EEG results correlate these phenomena with anomalous gamma-wave spikes in the prefrontal cortex. • Psychological regression: Mental deterioration accelerates sharply. Subjects demonstrate a return to primitive vocalizations and instinctual aggression, often attempting to bite or self-mutilate in response to external stimuli. Current experimentation involves a series of invasive neurochemical trials intended to isolate the virus’s mutagenic triggers. Subjects are sedated intermittently to allow for direct cerebral access via craniotomy, during which real-time observations of viral activity are logged using enhanced nanoscopic imaging probes. To date, no subject has survived beyond 38 hours post-stage 4 classification. However, Patafino’s Virology Task Force reports a marginal delay in neural decay following Compound IX-77 injection, suggesting a possible route for neuro-stabilization if administered in early stage 3. Further updates will follow pending autopsy of Subjects #17–. Note: This stage of research remains off-record to all external oversight committees. Data is to be reviewed solely by Patafino’s Level 9 clearance board.
A detailed report - read or listen (scroll down)
